Stock Ticker

  • Loading stock data...

Merck (NYSE:MRK) Receives Approval for KEYTRUDA From the EMA As First-Line MSI-H/dMMR Colorectal Cancer Treatment

Merck (NYSE:MRK) has announced that the European Medicines Agency’s Committee for Medicinal Product for Human Use has adopted a positive view recommending KEYTRUDA approval. EMA’s CHMP approves KEYTRUDA as MSI-H/dMMR cancer treatment KEYTRUDA is the company’s anti-PD-1 therapy used as a monotherapy for first-line mismatch repair deficient (dMMR) or metastatic microsatellite instability-high (MSI-H) colorectal cancer […]